FDA Greenlights J&J's Controversial Diabetes Drug
The U.S. Food and Drug Administration said Friday that it had approved Johnson & Johnson's Invokana, the first in a new class of diabetes drugs, less than three months after announcing...To view the full article, register now.
Already a subscriber? Click here to view full article